We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+38.74%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.72B
AUM Growth
+$518M
Cap. Flow
+$200M
Cap. Flow %
11.63%
Top 10 Hldgs %
67.52%
Holding
71
New
13
Increased
19
Reduced
9
Closed
13

Top Buys

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$43.8M
2
GILD icon
Gilead Sciences
GILD
+$30.4M
3
AZN icon
AstraZeneca
AZN
+$24.5M
4
ISRG icon
Intuitive Surgical
ISRG
+$20.7M
5
MRK icon
Merck
MRK
+$19.9M

Top Sells

Rank Stock Value
1
NVO
Novo Nordisk
NVO
+$30.5M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$21.1M
3
RGNX icon
Regenxbio
RGNX
+$16.7M
4
CCXI
ChemoCentryx, Inc.
CCXI
+$15.8M
5
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$11.3M

Sector Composition

Rank Sector Weight
1 Healthcare 91.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRTX
1
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$466M 27.13%
2,073,124
– –
CINC
2
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$200M 11.61%
6,079,949
+506,000
+9% +$14.3M
NTRA icon
3
Natera
NTRA
$37.5B
$136M 7.91%
3,102,960
– –
VERA icon
4
Vera Therapeutics
VERA
$2.54B
$67.8M 3.94%
3,181,442
– –
JBIO
5
Jade Biosciences
JBIO
$1.22B
$62.3M 3.63%
107,391
– –
ASND icon
6
Ascendis Pharma A/S
ASND
$16.7B
$51.6M 3%
499,824
– –
MRK icon
7
Merck
MRK
$324B
$50.2M 2.92%
583,468
+222,507
+62% +$19.9M
SNY icon
8
Sanofi
SNY
$104B
$48.1M 2.8%
1,264,546
+982,346
+348% +$43.8M
QQQ icon
9
PUT
Invesco QQQ Trust
QQQ
$455B
$40.1M 2.33%
+150,000
New +$45.3M
AZN icon
10
AstraZeneca
AZN
$263B
$38.5M 2.24%
350,939
+192,759
+122% +$24.5M
XLV icon
11
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$42.1B
$36.3M 2.11%
300,000
– –
IWM icon
12
PUT
iShares Russell 2000 ETF
IWM
$80.9B
$33M 1.92%
+200,000
New +$36.5M
YMAB
13
DELISTED
Y-mAbs Therapeutics
YMAB
$31.6M 1.84%
2,194,278
– –
UTHR icon
14
United Therapeutics
UTHR
$26.3B
$30.9M 1.8%
147,564
+41,185
+39% +$9.21M
GILD icon
15
Gilead Sciences
GILD
$161B
$29.8M 1.73%
+482,400
New +$30.4M
MRK icon
16
CALL
Merck
MRK
$324B
$25.8M 1.5%
+300,000
New +$26.8M
BMRN icon
17
BioMarin Pharmaceuticals
BMRN
$11.5B
$25M 1.45%
294,750
-6,855
-2% -$610K
CTIC
18
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$21M 1.22%
3,612,376
+907,866
+34% +$5.66M
RETA
19
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$20.6M 1.2%
818,376
+34,525
+4% +$957K
ISRG icon
20
Intuitive Surgical
ISRG
$121B
$18.1M 1.05%
+96,300
New +$20.7M
IRTC icon
21
iRhythm Holdings
IRTC
$3.59B
$17.6M 1.02%
140,095
-1,996
-1% -$288K
DXCM icon
22
DexCom
DXCM
$27.6B
$16.6M 0.97%
205,948
+16,856
+9% +$1.43M
SRPT icon
23
Sarepta Therapeutics
SRPT
$1.66B
$15.6M 0.91%
141,440
+10,195
+8% +$1.03M
CYTK icon
24
Cytokinetics
CYTK
$11B
$15.5M 0.9%
320,722
-58
-0% -$2.79K
ISEE
25
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$14.7M 0.86%
820,665
+167,618
+26% +$2.2M
1
2 3

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q3 2022 Portfolio in Review

As of Q3 2022, Sofinnova Investments held 71 positions worth $1.72B, up 43% from $1.2B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Sofinnova Investments deployed $200M of net new capital in Q3 2022, opening 13 new positions and adding to 19 existing holdings. Its largest new stake was Gilead Sciences: 482,400 shares worth $29.8M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 92% a quarter earlier.

On the sell side, the largest reduction was Regenxbio, an estimated $16.7M trimmed.

  • Sofinnova Investments's largest Q3 2022 buy was Gilead Sciences: 482,400 shares worth $29.8M.
  • Sofinnova Investments added most to Sanofi in Q3 2022, an estimated $43.8M increase.
  • Sofinnova Investments's biggest Q3 2022 reduction was Regenxbio, cutting an estimated $16.7M.
  • Sofinnova Investments fully exited Novo Nordisk in Q3 2022, selling an estimated $30.5M.
  • Sofinnova Investments's ten largest holdings make up 68% of its $1.72B portfolio in Q3 2022.
  • Sofinnova Investments opened 13 new positions and closed 13 in Q3 2022.
  • Sofinnova Investments's portfolio value rose 43% quarter-over-quarter to $1.72B.

Based on Sofinnova Investments's 13F filing for Q3 2022, filed 8 Nov 2022.